Efficacy and safety of fourth-generation CD19 CAR-T expressing IL7 and CCL19 along with PD-1 monoclonal antibody for relapsed or refractory large B-cell lymphoma

被引：0
|
作者：
俞腾
机构：
[1] Med Coll
[2] Zhejiang Univ
[3] Dept Hematol
[4] 2nd Affil Hosp
来源：
China Medical Abstracts(Internal Medicine) | 2024年 / 41卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R733.1 [网状内皮系统肿瘤];
学科分类号：
摘要：
Objective To explore the efficacy and safety of fourthgeneration chimeric antigen receptor T-cells (CAR-T),which express interleukin 7 (IL7) and chemokine C-C motif ligand 19 (CCL19) and target CD19,in relapsed or refractory large B-cell lymphoma.Methods Our center applied autologous 7×19 CAR-T combined with tirelizumab to treat 11 patients with relapsed or refractory large B-cell lymphoma.The efficacy and adverse effects were explored.
引用
收藏
页码：59 / 59
页数：1
相关论文
共 50 条
  • [41] CD19/CD22 CAR-T Cell Cocktail Therapy Following Autologous Transplantation in Patients with Relapsed/Refractory B-Cell Lymphomas
    Cao, Yang
    Xiao, Yi
    Wang, Na
    Wang, Gaoxiang
    Zhou, Xiaoxi
    Huang, Liang
    Chen, Liting
    Xiao, Min
    Zhang, Tongcun
    Zhang, Yicheng
    Zhou, Jianfeng
    BLOOD, 2020, 136
  • [42] Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma
    Roddie, Claire
    Neill, Lorna
    Osborne, Wendy
    Iyengar, Sunil
    Tholouli, Eleni
    Irvine, David
    Chaganti, Sridhar
    Besley, Caroline
    Bloor, Adrian
    Jones, Ceri
    Uttenthal, Ben
    Johnson, Rod
    Sanderson, Robin
    Cheok, Kathleen
    Marzolini, Maria
    Townsend, William
    O'Reilly, Maeve
    Kirkwood, Amy A.
    Kuhnl, Andrea
    BLOOD ADVANCES, 2023, 7 (12) : 2872 - 2883
  • [43] Efficacy and Safety of PD-1 Inhibitor Plus Rituximab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Qin, Yan
    He, Xiaohui
    Yang, Sheng
    Liu, Peng
    Zhou, Shengyu
    Yang, Jianliang
    Gui, Lin
    Zhong, Qiaofeng
    Zhao, Fengyi
    Shi, Yuankai
    Jing, Hongmei
    Zhang, Shiyue
    Guo, Ruihan
    Shi, Yuankai
    BLOOD, 2021, 138
  • [44] OUTCOMES OF COMMERCIAL AND IN-HOUSE ANTI CD19 CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY B-CELL LYMPHOMA IN SINGAPORE
    Ong, Shin Yeu
    Krisnadi, Cindy
    Wang, Samuel Sherng Young
    Chen, Yun Xin
    Seng, Michaela Su-fern
    Soh, Shui Yen
    Chan, Esther Hian Li
    Hwang, William Ying Khee
    Ho, Aloysius Yew Leng
    Lim, Francesca Lorraine Wei Inng
    BONE MARROW TRANSPLANTATION, 2024, 59 : 226 - 226
  • [45] Inflammatory Biomarker Clusters Are Predictive of Response and Toxicity in Large B-Cell Lymphoma Treated with CD19 CAR-T Cell Therapy
    Raj, Sandeep
    Perales, Miguel-Angel
    Fein, Joshua A.
    Tomas, Ana Alarcon
    Batlevi, Connie Lee
    De Lapuerta, Magdalena Corona
    Dahi, Parastoo B.
    Danylesko, Ivetta
    Fried, Shalev
    Funnell, Tyler
    Giralt, Sergio A.
    Jacoby, Elad
    Kedmi, Meirav
    Lin, Richard J.
    Nagler, Arnon
    Nath, Karthik
    Parascondola, Allison
    Palomba, M. Lia
    Salles, Gilles
    Scordo, Michael
    Shah, Gunjan L.
    Shem-Tov, Noga
    Shimoni, Avichai
    Slingerland, John
    Walji, Moneeza
    Yerushalmi, Ronit
    Avigdor, Abraham
    van den Brink, Marcel R. M.
    Shouval, Roni
    BLOOD, 2022, 140
  • [46] A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma
    Zhitao Ying
    Ting He
    Shanzhao Jin
    Xiaopei Wang
    Wen Zheng
    Ningjing Lin
    Meifeng Tu
    Yan Xie
    Lingyan Ping
    Weiping Liu
    Lijuan Deng
    Yanping Ding
    Xuelian Hu
    Bing Bu
    Xin'an Lu
    Yuqin Song
    Jun Zhu
    ChineseJournalofCancerResearch, 2022, 34 (01) : 53 - 67
  • [47] Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (02) : 13 - 15
  • [48] CD19 CAR T-CELLS FOR RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: REAL-WORLD DATA FROM LMU MUNICH
    Bucklein, V.
    Blumenberg, V.
    Schmidt, C.
    Rejeski, K.
    Ruzicka, M.
    Mueller, N.
    Reischer, A.
    von Baumgarten, L.
    Voelkl, A.
    Wagner, B.
    Humpe, A.
    Tischer, J.
    Stemmler, H.
    von Bergwelt, M.
    Subklewe, M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A48 - A49
  • [49] A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma
    Ying, Zhitao
    He, Ting
    Jin, Shanzhao
    Wang, Xiaopei
    Zheng, Wen
    Lin, Ningjing
    Tu, Meifeng
    Xie, Yan
    Ping, Lingyan
    Liu, Weiping
    Deng, Lijuan
    Ding, Yanping
    Hu, Xuelian
    Bu, Bing
    Lu, Xin'an
    Song, Yuqin
    Zhu, Jun
    CHINESE JOURNAL OF CANCER RESEARCH, 2022, 34 (01)
  • [50] Safety and Efficacy of Low Dose CD19 Targeted Chimeric Antigen Receptor T (CAR-T) Cell Immunotherapy in 47 Cases with Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)
    Deng, Biping
    Chang, Alex Hongsheng
    Yang, Junfang
    Pan, Jing
    Zhang, Xian
    Lin, Yuehui
    Wu, Yanan
    Deng, Zhenling
    Lu, Peihua
    Wu, Tong
    Liu, Zhaoli
    Zhang, Yu'e
    Tong, Chunrong
    BLOOD, 2016, 128 (22)
12345